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ORIGINAL RESEARCH
Restless Legs Syndrome Shows Increased 
Silent Postmortem Cerebral Microvascular 
Disease With Gliosis
Arthur S. Walters , MD; Paisit Paueksakon, MD; Charles H. Adler , MD, PhD; Michael Moussouttas, MD; 
Leonard B. Weinstock , MD; Karen Spruyt , PhD; Kanika Bagai, MD, MSCI
BACKGROUND: Patients with restless legs syndrome (RLS) have increased silent microvascular disease by magnetic resonance 
imaging. However, there has been no previous autopsy confirmation of these magnetic resonance imaging findings. RLS is 
also frequently associated with inflammatory and immunologically mediated medical disorders. The postmortem cortex in 
patients with RLS was therefore evaluated for evidence of microvascular and immunological changes.
METHODS AND RESULTS: Ten microvascular injury samples of precentral gyrus in 5 patients with RLS (3 men, 2 women; mean 
age, 81 years) and 9 controls (2 men, 7 women; mean age, 90 years) were studied by hematoxylin and eosin stains in a blinded 
fashion. None of the subjects had a history of stroke or neurologic insults. In a similar manner, the following immunohisto-
chemistry stains were performed: (1) glial fibrillary acidic protein (representing gliosis, reactive change of glial cells in response 
to damage); (2) CD3 (a T- cell marker); (3) CD19 (a B- cell marker); (4) CD68 (a macrophage marker); and (5) CD117 (a mast cell 
marker). Patients with RLS had significantly greater silent microvascular disease (P=0.015) and gliosis (P=0.003). T cells were 
increased in RLS compared with controls (P=0.009) and tended to colocalize with microvascular disease (P=0.003). Other 
markers did not differ. There was no correlation between microvascular lesion load and RLS severity or duration.
CONCLUSIONS: Patients with RLS had statistically significantly more silent cerebral microvascular disease and gliosis than 
controls compatible with previous magnetic resonance imaging studies and with studies showing a link between RLS and 
hypertension, clinical stroke, and cardiovascular disease. T- cell invasion may be a secondary phenomenon.
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Numerous studies over the past decade and more have suggested that restless legs syn-drome (RLS) is associated with hypertension, 
heart disease, and stroke.1,2 Magnetic resonance 
images, for example, have shown that RLS and its 
accompanying periodic limb movements in sleep 
are characterized by greater levels of silent cere-
bral microvascular disease, a known risk factor for 
stroke.3,4 However, there has been no previous au-
topsy confirmation of these magnetic resonance 
imaging findings, which is one of the goals of the 
current study.
Another trajectory of research has been an inves-
tigation into the relationship of RLS with inflammatory 
and immunologic disorders. Many of the comorbid 
disorders more frequently associated with RLS have 
an inflammatory or autoimmune diathesis, including 
multiple sclerosis, rheumatoid arthritis, celiac disease, 
Crohn disease, inflammatory bowel disease, small in-
testinal bacterial overgrowth, and, most recently, mast 
cell activation syndrome.5– 9 Mast cells play a role in al-
lergy, anaphylaxis, wound healing, angiogenesis, im-
mune tolerance, and defense against pathogens.9 The 
primary goal of the current study is to document with 
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postmortem examination the degree of silent cerebral 
microvascular disease and gliosis in RLS. The precen-
tral gyrus (motor cortex) was chosen, as neurophys-
iologic studies have used it as a focus of interest in 
showing that suprasegmental disinhibition is a major 
feature of RLS.10 A secondary goal, based on previous 
studies demonstrating links between RLS and inflam-
matory and autoimmunity mechanisms, was to deter-
mine if inflammatory markers are also present in RLS 
cortex, and third, to see if microvascular lesions and 
inflammatory markers colocalize.
METHODS
Data, Materials, and Code Disclosure 
Statement
The data that support the findings of this study are 
available from Paisit Paueksakon, MD, Professor, 
Associate Director Division of Renal Pathology/
Electron Microscopy and Renal Pathology Fellowship, 
Division of Neuropathology, Department of Pathology, 
Microbiology, and Immunology, Vanderbilt University 
Medical Center (C- 23188 Medical Center North, 1161 
21st Ave South, Nashville, TN 37232, Tel: 615- 322- 
1350; FAX, 615- 322- 4840; E- mail: Paisit.Paueksakon@
VUMC.org).
A review of the protocol for this study was done by 
the Vanderbilt University Medical Center Institutional 
Review Board and was declared “nonresearch” from 
an Institutional Review Board point of view, and no in-
formed consent was required.
Precentral gyrus (motor cortex) samples were 
obtained from 5 patients with RLS and 9 con-
trols from the AZSAND (Arizona Study of Aging and 
Neurodegenerative Disorders) and the Banner Sun 
Health Research Institute Brain and Body Donation 
Program.11 Subjects were defined as having RLS if they 
met the 4 basic clinical criteria for RLS: (1) an urge to 
move the legs, (2) worsening of symptoms later in the 
day or at night, (3) worsening of symptoms when lying 
or sitting, and (4) at least partial and temporary relief 
by activity. Those who did not meet the criteria for RLS 
qualified as controls.
All subjects completed a movement disorders ex-
amination with questions regarding RLS as well as 
the Mayo Sleep Questionnaire.11 The subjects cho-
sen all had a long- standing history of RLS. The sever-
ity of RLS was rated within ≈3 years of death by the 
International Restless Legs Severity Scale. Subjects 
had to meet the criteria above for RLS to be admin-
istered the International Restless Legs Severity Scale. 
The International Restless Legs Severity Scale is a 
previously validated instrument consisting of 10 ques-
tions, where each question is rated from 0 (no RLS 
symptoms) to 4 (maximum RLS severity), and then the 
scores for each individual question are added to obtain 
a total score (0=no RLS symptoms to 40=maximum 
RLS symptoms).12
Exclusion Criteria
In a first round of exclusions, subjects and controls 
with a known clinical history of previous stroke or a 
history of Alzheimer disease, dementia, head trauma, 
Parkinson disease, brain tumor, multiple sclerosis, 
or other neurodegenerative disorders were excluded 
from the study. In a second round of exclusions, sub-
jects and controls who had neuropathologic evidence 
CLINICAL PERSPECTIVE
What Is New?
• Previous work has shown that patients with 
restless legs syndrome (RLS) and its frequently 
co- occurring periodic limb movements in sleep 
have more silent cerebral microvascular dis-
ease by magnetic resonance imaging; RLS has 
also been associated with inflammation and 
autoimmunity.
• To our knowledge there has been no autopsy 
confirmation of the magnetic resonance imag-
ing findings and no autopsy study looking for 
autoimmune markers in RLS; in this autopsy 
study of the cerebral cortex, we show that there 
is more silent microvascular disease and ac-
companying gliosis in patients with RLS versus 
controls.
• T- cell invasion reflective of cellular autoimmunity 
is also more prominent, and there is no upregu-
lation of CD19 (a B- cell marker), CD68 (a mac-
rophage marker), or CD117 (a mast cell marker).
What Are the Clinical Implications?
• This study is compatible with previous magnetic 
resonance imaging studies and with studies 
showing a link between RLS and hypertension, 
clinical stroke, and cardiovascular disease.
• This study is also compatible with our previous 
study showing that the treatment of RLS with 
RLS medications lowers the associated cardio-
vascular risk.
• Upregulated T- cell levels in patients with RLS 
could be predisposing factors for develop-
ment of microvascular disease or a secondary 
phenomenon.
Nonstandard Abbreviations and Acronyms
AZSAND Arizona Study of Aging and 
Neurodegenerative Disorders




 http://ahajournals.org by on Septem
ber 13, 2021
J Am Heart Assoc. 2021;10:e019627. DOI: 10.1161/JAHA.120.019627 3
Walters et al RLS and Cerebral Microvascular Disease
of stroke, Alzheimer disease, other dementia, head 
trauma, Parkinson disease, brain tumor, multiple 
sclerosis, or other neurodegenerative disease were 
excluded, and at this stage, 1 subject was excluded 
because of intraparenchymal hemorrhage.
Studies performed on specimens:
1. Microvascular injuries (such as intimal fibrosis of 
arteries, which correlates with vascular smooth 
muscle hyperplasia) with hematoxylin and eosin 
stain.
2. Glial fibrillary acidic protein to look for gliosis, which 
is a response to brain injury and is a proliferation or 
hypertrophy of the glial cells, which are supporting 
cells to the neurons.
3. CD3— look for increase in T cells (cellular immunity).
4. CD19— look for increase in B cells (humoral immu-
nity or antibodies).
5. CD68— look for increase in macrophages (first- line 
immunologic attack cells).
6. CD 117— look for increase in mast cells (play multiple 
roles in immunologic mechanisms).
7. Amyloid beta- peptide and tau protein to look for 
neuritic plaques and neurofibrillary tangles to ex-
clude past brain injury from Alzheimer disease.
8. Ten areas of precentral gyrus of cortex (the motor 
cortex) were examined in a blinded fashion for each 
subject and rated 0 to 3+ for each entity of interest 
by previously described methods.13 The total of rat-
ings for each of 10 areas per patient were added 
to get the sum score and then divided by 10 to get 
the average. In the above system, 0= no markers 
of interest; 1=1 marker of interest; 2=2 to 5 markers 
of interest; and 3=>5 markers of interest. If an im-
munologic marker showed a statistically significant 
difference between subjects with RLS and controls, 
colocalization of immunologic markers and micro-
vascular disease was determined by the number of 
immunologic markers per vascular cross section by 
the same methodology.
A detailed description of tissue processing and immuno-
histochemistry including light microscopy and immuno-
histochemical studies can be found in Data S1.
Statistical Analysis
A stepwise analytic approach was conducted. Primary 
variables were microvascular lesion load and glio-
sis. Secondary variables were inflammatory markers. 
Tertiary variables were RLS duration and severity and 
past medical history. The Mann- Whitney U test was 
applied to assess group differences for continuous 
variables, and Fisher’s exact text was applied for cat-
egorical variables. The correlation of RLS duration and 
RLS severity to microvascular lesion load was per-
formed by Spearman’s rho. Post hoc, we calculated 
the Hedges’ g, which is an effect- size measure, and 
calculated the power of that effect size.
Statistical analyses were performed with Statistica 
version 13 (TIBCO Software Inc, Palo Alto, CA).
RESULTS
We evaluated 5 RLS patients (3 men and 2 women; 
mean age, 81 years; range, 65– 93 years) and 9 con-
trols (2  men and 7  women; mean age, 90.2  years; 
range, 78– 99 years). Table 1 gives the demographic in-
formation for subjects and controls in the study. There 
was no statistically significant difference in age or sex 
between patients and controls (Table 1). Of the 5 sub-
jects who had RLS, 1 subject was on hydrocodone, 
1 on clonazepam, 1 on both ropinirole and tramadol 
for treatment of RLS, and 2 subjects were on no RLS 
treatment (Table 1).
Primary Variables
Table  2 gives individual subject information for the 
markers of interest. There was a significant difference 
in the extent of silent cerebral microvascular disease 
(P=0.015) (Figure 1 and Table 3) and the level of glio-
sis (P=0.003) (Figure  2 and Table  3) in patients with 
RLS compared with controls. All patients and controls 
were negative for amyloid beta- protein and tau protein 
(Tables 2 and 3).
Secondary Variables
T cells were also increased in RLS compared with con-
trols (P=0.009) (Figure 3 and Table 3). T cells tended to 
colocalize with microvascular disease, and the colo-
calization was significantly greater in patients with RLS 
than controls (P=0.003) (Table 3).
By Mann- Whitney U test there was no significant 
difference between patients and controls in CD68 
(U=22; Z=0; P=1.0) or CD117 (U=18; Z=−0.21958; 
P=0.825) (Table 3). There was no evidence of CD19 
B- cell antibody production in patients or controls 
(Tables 2 and 3).
Tertiary Variables
Given the small sample size and the fact that not 
all the secondary variables differed significantly be-
tween groups, further analysis should be considered 
exploratory. There was no significant correlation by 
Spearman’s rho between RLS duration (rs=0.72; 
P=0.17) or severity (rs=−0.41; P=0.49) and micro-
vascular lesion load (Table  1). Chi- square analysis 
did not find a significant imbalance of cardiovascu-
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failure, coronary artery disease, cardiac valve dis-
ease, cardiac arrhythmia, cardiomegaly) between 
the RLS group (3/5 subjects) and the control group 
(8/9 subjects) group. By chi- square there was also 
no significant difference in other types of cardiovas-
cular risk factors between the groups such as diabe-
tes mellitus (1/5 versus 1/9), hypertension (2/5 versus 
7/9), or hyperlipidemia (2/5 versus 6/9). In addition, 
chi- square did not show an imbalance of cancer be-
tween the RLS group (3/5 subjects) and the controls 
(3/9 subjects).
DISCUSSION
The major finding in this autopsy- based study was 
that in subjects without a previous history of stroke 
or any other neurologic disease, silent ischemic cer-
ebrovascular disease and gliosis in the motor cortex 
were more common in RLS subjects than controls. 
These findings support previous magnetic reso-
nance imaging findings of an increase in leukoariotic 
cerebrovascular disease in patients with RLS and its 
allied condition periodic limb movements in sleep 
compared with controls.3,4
Additionally, T- cell infiltration was more common 
in subjects with RLS than in controls. These findings 
also support previous findings of a link between 
RLS and inflammation.5 The immunologic alteration 
in the current study suggests that cellular immunity 
may be altered in RLS, given the increased T- cell 
invasion (CD3) we found as opposed to humoral 
or antibody immunity (CD19— B cells), the first line 
immunologic attack system (CD68— macrophages), 
or allergy/anaphylaxis (CD117— mast cells). On the 
other hand, these data are also compatible with the 
normal response of the brain to ischemia. At the le-
sion border in acutely ischemic areas, there is initially 
an invasion of polymorphonuclear leukocytes fol-
lowed soon after by T lymphocytes, B lymphocytes, 
mast cells, and activation of microglia. Over the next 
few days there is an invasion of macrophages that 
eventually become the predominant inflammatory 
cell, but evidence also exists that T cells are the leu-
kocytic lineage that may persist for the longest time 
after ischemia.14– 19 Leukocytic activity during acute 
cerebral ischemia may contribute to the inflamma-
tory process and to neuronal injury but may also 
later provide protective and reparative functions to 
the damaged area. Increased T- cell activation in our 
patients with RLS may simply be compatible with 
the increased microvascular lesion load in these 
subjects, and may represent a secondary adaptive 
neuroprotective response to prior ischemia. On the 
other hand, we cannot exclude the possibility that 
the T- cell presence represents an immune manifes-
tation of RLS. One would assume that the microvas-
cular lesions have been present for some time, long 
after one would expect macrophage and mast cell 
invasion. Macrophages and mast cells were present 
in both our patients with RLS and controls, but no 
difference was noted in the degree to which these 
cell types were present between the 2 groups. The 
Table 1. Clinical Characteristics of the Patients With RLS and Controls
Patient No. Age, y Sex RLS Duration, y
RLS Severity 
Score
Time From IRLS Score 
to Autopsy RLS Treatment
1 93 F 2 4 3 mo None
2 79 M 8 12 39 mo Hydrocodone
3 80 M 13 15 5 mo Clonazepam
4 65 M 3 28 24 mo Ropinirole tramadol
5 88 F 27 9 16 mo None
Control no. Age, y Sex … … …
1 88 F … … …
2 78 F … … …
3 87 F … … …
4 91 M … … …
5 84 F … … …
6 96 M … … …
7 99 F … … …
8 93 F … … …
9 96 F … … …
RLS severity score is the IRLS, a previously validated scale in which 10 questions are each rated from 0 (no RLS symptoms) to 4 (maximum RLS symptoms) 
and then totaled (range, 0– 40). RLS treatment is indicated as treatment at the time of death. There is no statistically significant difference in age (U=11; P=0.14) 
or sex (P=0.2657 by 2- tailed Fisher’s exact test) between patients and controls. There was not a statistically significant correlation by Spearman’s rho between 
RLS duration (rs=−0.72; P=0.17) or severity (rs=−0.41; P=0.49) and microvascular lesion load. IRLS indicates International Restless Legs Syndrome Severity 
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fact that T cells are more prominent in the subjects 
than the controls suggest that the microvascular le-
sions observed are chronic rather than acute since 
T cells persist in the context of vascular insult long 
after other cell types have diminished or disap-
peared.14– 19 Other cell types may have diminished 
to the point that previous differences between sub-
jects and controls, in the degree to which these cell 
types were present, are no longer detectable.
The major limitation to this study was the small 
sample size. Autopsy cases of subjects with RLS hav-
ing little to no other neurologic abnormality clinically or 
neuropathologically is very rare. As our methodology 
excluded subjects with other neurologic insults, our 
sample size was of necessity small. Another limitation 
was the possibility that RLS treatment could cause 
the microvascular disease, but this is unlikely given 
a previous study showing that treatment ameliorates 
Figure 1. Examples of level of microvascular injury score in controls (A and B) and patients with 
restless legs syndrome (RLS) (C and D).
A, Score 0; B, score 1; C, score 2; and D, score 3. There is marked increase in microvascular injury in 
patients with RLS characterized by intimal fibrosis of artery (arrow). Hematoxylin and eosin stain, ×200. 
Patients with RLS had significantly greater silent microvascular disease than controls (P=0.015). See 
details in Tables 2 and 3.
A B
C D
Table 3. Statistical Comparison Between RLS and Control Group
RLS Control
Test Statistic Hedges’ g Power, %M±SD Mdn (QR) M±SD Mdn (QR)
Microvascular injury 
score
2.3±1.1 2.9 (1) 0.7±0.8 0.2 (1.0) U=4, P=0.015 1.6±0.6 77.2
CD3 score 0.3±0.2 0.2 (0.3) 0.0±0.1 0.0 (0.0) U=4, P=0.009 2.0±0.6 90.4
CD3 MC score 1.7±0.6 2.1 (1) 0.6±0.3 0.6 (0.6) U=0, P=0.003 2.4±0.7 97.8
CD19 score 0 0 0 0
CD68 score 0.3±0.4 0.1 (0) 0.2±0.2 0.1 (0.0) U=22, P=1 0.3±0.5 8.5
CD117 score 1.7±0.6 2.0 (0.9) 1.8±0.2 1.9 (0.4) U=18, P=0.825 −0.2±0.5 6.9
GFAP score 2.3±0.4 2.2 (0.1) 0.5±0.6 0.2 (0.9) U=0, P=0.003 3.1±0.8 99.9
Amyloid beta- peptide 
score
0 0 0 0
Tau protein score 0 0 0 0
Patients with RLS had significantly greater silent microvascular disease (P=0.015) and gliosis as demonstrated by GFAP (P=0.003). T cells, as demonstrated 
by CD3, were increased in RLS compared with controls (P=0.009) and tended to colocalize with microvascular disease (P=0.003). Other markers did not differ. 
The Hedges’ g statistic indicates the effect size for the difference between means. Power=1−β error probability, for 2- tailed α. CD3 MC score indicates T cell 
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the likelihood of developing future cardiovascular 
disease.20
Considerations for future research into the immu-
nopathogenesis of RLS include flow cytometry to look 
for differences in the T- cell subtypes between subjects 
with RLS and controls as well as RNA sequencing rel-
evant to T- cell functioning.
CONCLUSIONS
Patients with RLS had statistically significantly more 
silent cerebral microvascular disease and gliosis 
than controls, compatible with previous magnetic 
resonance imaging studies and with studies show-
ing a link between RLS/periodic limb movements in 
Figure 2. There is a marked increase in gliosis as demonstrated by GFAP (glial fibrillary acidic 
protein) in patients with restless legs syndrome (RLS) (A) compared with controls (B) (P=0.003).
The arrow points to perivascular astrocytes (anti- GFAP stain, ×200). See details in Tables 2 and 3.
A B
Figure 3. Examples of level of T- cell (CD3) staining score in controls (A and B) and patients with 
restless legs syndrome (RLS) (C and D).
A, Score 0; B, score 1; C, score 2; and D, score 3. There is marked increase in CD3 staining in patients with 
RLS (arrow). Anti- CD3 stain, ×200. T cells, as demonstrated by CD3, were increased in RLS compared 
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sleep and hypertension, clinical stroke, and cardi-
ovascular disease. Upregulated T- cell levels in pa-
tients with RLS could be predisposing factors for 
development of microvascular disease or a second-
ary phenomenon.
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Tissue processing and Immunohistochemistry 
Light microscopy 
      Briefly, brain tissues were fixed in buffered formaldehyde, dehydrated in graded 
alcohols, and embedded in paraffin using standard techniques. Serial 5 µm-thick 
sections were cut and stained with hematoxylin and eosin reagent.  
Immunohistochemical studies 
For CD3 detection, 5 µm-thick paraffin-embedded sections were cut, deparaffinized, 
rehydrated. Slides were placed on the Leica Bond Max IHC stainer. All steps besides 
dehydration, clearing and coverslipping are performed on the Bond Max. Slides were 
deparaffinized. Heat induced antigen retrieval was performed on the Bond Max using 
their Epitope Retrieval 2 solution for 20 minutes. Slides were incubated with Ready-To-
Use anti-CD3 (Cat# MM150-10, StatLab McKinney, TX) for one hour. The Bond 
Polymer Refine system was used for visualization. Slides were the dehydrated, cleared 
and coverslipped. 
For CD19, CD68, and CD117 detection, 5 µm-thick paraffin-embedded sections were 
cut, deparaffinized, rehydrated. Slides were placed on the Leica Bond Max IHC stainer. 
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Max. Slides are deparaffinized. Heat induced antigen retrieval was performed on the 
Bond Max using their Epitope Retrieval 1 solution for 20 minutes. Slides were incubated 
with Ready-To-Use anti-CD19 (PA0843, Leica Biosystems, Newcastle, Tyne, NE, UK), 
Ready-To-Use anti-CD68 (MM36-10, StatLab, McKinney, TX), and Ready-To-Use anti-
CD117 (PA0007, Leica Biosystems, Newcastle, Tyne, NE, UK) for 15minutes.  The 
Bond Polymer Refine detection system was used for visualization. Slides were the 
dehydrated, cleared and coverslipped. 
 
For GFAP detection, 5 µm-thick paraffin-embedded sections were cut, deparaffinized, 
rehydrated. Slides were placed on the Leica Bond Max IHC stainer. All steps besides 
dehydration, clearing and coverslipping are performed on the Bond Max. Slides were 
deparaffinized. Heat induced antigen retrieval was performed on the Bond Max using 
their Epitope Retrieval 2 solution for 5 minutes. Slides were incubated with Ready-To-
Use anti-GFAP (PA0026, Leica Biosystems, Newcastle, Tyne, NE, UK) for 15minutes.  
The Bond Polymer Refine detection system was used for visualization. Slides were the 
dehydrated, cleared and coverslipped. 
Normal lymphoid tissue was used as a positive control for CD3, CD19, and CD68. 
Normal gastric tissue was used as a positive control for CD117. Brain tissue with 
reactive gliosis was used as a positive control for GFAP. Negative controls were done 
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